drugset
Drugs / AZD7009
last change May 2006 re-read 3 minutes ago

AZD7009

also known as AR H065522XX

Small molecule targets KCNH2, SCN5A via inhibition

Developed for
atrial fibrillation
Investigated by
AstraZeneca

Trials 1

today NCT00255281 · Ph 2
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00255281 Sep 2005 → May 2006 atrial fibrillation AstraZeneca Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as AZD7009 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00255281 ↗
Known as AR H065522XX “AZD7009 (AR H065522XX) Given Intravenously” NCT00255281 ↗
Action Inhibit “Sodium channel protein type V alpha subunit blocker” CHEMBL3545040 ↗
1

“HERG blocker” CHEMBL3545040 ↗
Modality Small molecule — CHEMBL3545040 ↗
Route Intravenous “AZD7009 (AR H065522XX) Given Intravenously” NCT00255281 ↗
Target KCNH2 “HERG blocker” CHEMBL3545040 ↗
Target SCN5A “Sodium channel protein type V alpha subunit blocker” CHEMBL3545040 ↗